Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

NCT06449482 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped The number of participants in the study did not meet expectations

Conditions

Acute Myeloid Leukemia, Adult

Interventions

DRUG: Selinexor
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China